14-day Premium Trial Subscription Try For FreeGet Free
Currently predicting for Mon, 4 Dec 2023

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 7.53 5.51 %
R2 7.31 2.35 %
R1 7.17 0.402 %
Current price: 7.14
Support S1 6.72 -5.91 %
S2 6.58 -7.86 %
S3 6.35 -11.02 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 7.92 10.92 %
R2 7.86 10.08 %
R1 7.35 2.94 %
Current price 7.14
Support S1 6.78 -5.04%
S2 6.73 -5.74%
S3 6.18 -13.45%

QURE Predictions History

3 years ago
StockVader predicted that QURE for 2019-12-05 is going

3 years ago
PumpTheseNumbers predicted that QURE for 2019-12-05 is going $63.09 (-2.31%)

3 years ago
JS predicted that QURE for 2019-12-05 is going $66.07 (2.31%)

3 years ago
Irmantas Bačiulis predicted that QURE for 2019-12-05 is going

Rank:

3 years ago
RobertJordan129117 predicted that QURE for 2019-12-05 is going $64.00 (-2.11%)

Rank:

4 years ago
joe1234 predicted that QURE for 2019-05-13 is going $62.92 (9.08%)

4 years ago
NameNotImportant predicted that QURE for 2019-05-06 is going $58.76 (0.03%)

4 years ago
NameNotImportant predicted that QURE for 2019-05-03 is going $61.84 (5.28%)

4 years ago
NameNotImportant predicted that QURE for 2019-04-29 is going $58.76 (3.74%)

Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT